Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.
A groundbreaking analysis of how well animal studies predict human safety will lead to reduced animal testing and better clinical results for patients, it is hoped.
As part of pharmaphorum’s ‘eye-on-innovation’ interview series, Paul Tunnah speaks to Bayer’s Chief Marketing Officer Pharmaceuticals, Sebastian Guth, on his views on how the synergy of pharma
